CQS (US)’s Editas Medicine EDIT Stock Holding History

CQS (US)’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-336,842	Closed	-$6.41M	–	100
2022 Q1	$6.41M	Buy	+336,842	New	+$6.26M	0.44%	70

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

CQS (US)'s EDIT Position: Q2 2022 in Review

CQS (US) sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 336,842 shares — an estimated $6.41M sold.

CQS (US) first reported a position in EDIT in Q1 2022 and held it in 1 quarter. The position peaked at $6.41M in Q1 2022. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

CQS (US) reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
CQS (US) sold 336,842 Editas Medicine shares in Q2 2022, an estimated $6.41M.
CQS (US) first reported a position in Editas Medicine in Q1 2022 and held it in 1 quarter.
CQS (US)'s Editas Medicine position peaked at $6.41M in Q1 2022.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on CQS (US)'s 13F filing for Q2 2022, filed 12 Aug 2022.